Single peptide Vial strength 10 mg
FOXO4-DRI10 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
FOXO4-DRI, explained simply
A synthetic peptide studied for its interaction with senescent cells, which have stopped dividing and may affect surrounding tissue.
Research area
Cellular senescence and tissue ageing
How it works
Designed to disrupt the FOXO4–p53 interaction in senescent cells, promoting programmed cell death in experimental models.
Why it matters
Research asks whether selectively removing senescent cells can affect tissue function with age.
What has been observed
Laboratory and animal studies describe changes in senescent-cell burden and tissue function.
Effects and points to consider
Clinical evidence for efficacy and safety in humans is lacking.
01 / Vial strength 10 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 10 mg FOXO4-DRI |
|---|---|
| Final volume | 3 mL |
| Concentration | 3.33 mg/mL |
| One U-100 unit | 33.33 mcg in 0.01 mL |
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg | 7.5 units (0.075 mL) |
| Weeks 5–8 | 375 mcg | 11 units (0.11 mL) |
| Weeks 9–12 | 500 mcg | 15 units (0.15 mL) |
| Weeks 13–16 | 500 mcg | 15 units (0.15 mL) |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.